Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs Topotecan in Second-Line Small Cell Lung Cancer
NCT02963090Phase 2Terminated
- Sponsor
- Alliance Foundation Trials
- Start
- May 2017
- Primary completion
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in small cell lung cancer (SCLC), sponsored by Alliance Foundation Trials. Started May 2017; status: terminated.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02963090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963090.